Investor profile
Archangel Investors Limited (Archangels)
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Archangels is the world's longest continuously operating business angel syndicate, founded in 1992 and based in Edinburgh. It provides carefully-curated investment opportunities to its ~120 high-net-worth members, deploying more than £10 million per year into early-stage Scottish technology and life sciences companies. The firm's core criteria are to invest as lead investor in businesses located and registered in Scotland, focusing on B2B technology, software and healthcare where scalability can be achieved without large capex requirements. Archangels targets deep, disruptive, protectable technologies that confer defensibility and create market pull, addressing large international markets. Beyond capital, the syndicate provides rigorous due diligence, governance support, board-level oversight, and access to its extensive network of experienced investors and industry contacts — with an average holding period of over eight years from initial investment to exit.
Notable quotes
“The co-investment agreement from British Business Investments means that, in a challenging global market, Archangels will have access to significant levels of aligned co-investment capital. This additional funding will allow us to support current and future portfolio companies to grow their businesses and provide returns for both our investors and the broader Scottish economy.”
“The level of activity we have seen from our members and partners in 2025 reflects the strength of Scotland's scale-up ecosystem and the quality of Archangels' portfolio. The growth ambition demonstrated by Scotland's scale-ups continues to impress, and the near £30m of co-investment we've been able to leverage alongside our investments demonstrates the appeal of these companies among the wider investor community.”
“BIOCAPTIVA is at an inflection point in its growth trajectory with the launch of its new msX beads. The market potential for the technology is remarkable, and with the products, the senior leadership and the research and development capability within the business, we're confident about the future success of the BIOCAPTIVA.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Bioliberty | Series A | $11m | 2026-03-19 |
| Earth Blox | Series A | $8m | 2026-03-18 |
| BioCaptiva | Seed | $2m | 2026-03-09 |
| 1nhaler | Seed | $2m | 2025-11-24 |
| PowerPhotonic | Seed | $3m | 2025-08-20 |
| CSignum | Series A | $8m | 2025-04-22 |
| Neuranics | Seed | $8m | 2025-04-09 |
| BDD Pharma | Seed | $3m | 2025-04-08 |
| Blackford Analysis | Series A | — | 2022-01-01 |
| Optos | Seed | — | — |
Frequent co-investors
Fit check
Is Archangel Investors Limited (Archangels) a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit